Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 6/20 | 0.76 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 2/20 | 0.99 |
| ▸ | GAA | P10253 | 2/20 | 0.99 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.99 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.99 |
| ▸ | LMNA | P02545 | 1/20 | 0.99 |
| ▸ | HPGD | P15428 | 1/20 | 0.99 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.99 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.99 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.97 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.97 |
| ▸ | MMP1 | P03956 | 1/20 | 0.97 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | ACHE | P22303 | 1/20 | 0.97 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irinotecan SCHEMBL359364 | 1.00 | PAX8 (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL30822976 | 1.00 | PAX8 (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL572716 | 1.00 | PAX8 (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL29363805 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL663859 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL5693425 | 0.99 | PAX8 (0.99) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL4033 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL31175855 | 0.99 | PAX8 (0.99) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL4450369 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL16447653 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2166 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094686-A | Oncolytic adenovirus and topoisomerase I inhibitors for the treatment of cancer | — | 2026-05-26 | — | — | CN | claimed |
| US-12527796-B2 | [6R]-MTHF—an efficient folate alternative in 5-fluorouracil based chemotherapy | ISOFOL MEDICAL AB (SE) | 2026-01-20 | — | — | US | claimed |
| US-20250298025-A1 | METHODS FOR THE DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-09-25 | — | — | US | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| EP-3840741-B1 | PLK1 TARGET PHOSPHORYLATION STATUS AND TREATMENT OF CANCER WITH PLK1 INHIBITORS | CARDIFF ONCOLOGY INC (US) | 2025-07-16 | — | — | EP | claimed |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | claimed |
| WO-2025080639-A1 | SUGAR NUCLEOTIDE CLEARANCE IN CANCER THERAPY | UNIVERSITY OF MASSACHUSETTS (US) | 2025-04-17 | — | — | WO | claimed |
| EP-4537114-A1 | METHODS FOR THE DETECTION AND TREATMENT OF CANCER | Board of Regents, The University of Texas System (US) | 2025-04-16 | — | — | EP | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| WO-2025062359-A1 | ONCOLYTIC ADENOVIRUS AND TOPOISOMERASE I INHIBITORS FOR USE IN TREATING A CANCER | THERIVA BIOLOGICS, S.L. (ES) | 2025-03-27 | — | — | WO | claimed |
| CN-112366830-B | Intelligent high-reliability low-voltage power supply and distribution system based on radial wiring and method thereof | 北京中煤矿山工程有限公司 | 2022-11-22 | — | — | CN | claimed |
| EP-4084822-A1 | INDIVIDUALIZED VACCINES FOR CANCER TREATMENT AND PREVENTION | Mayo Foundation for Medical Education and Research (US) | 2022-11-09 | — | — | EP | claimed |
| WO-2022229907-A1 | ANTIMICROBIAL AND ANTICANCER AGENTS | GEISTLICH PHARMA AG (CH) | 2022-11-03 | — | — | WO | claimed |
| CN-114948963-A | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-08-30 | — | — | CN | claimed |
| CN-114569603-A | Application of artemether in improving nonalcoholic steatohepatitis | 中国农业大学 | 2022-06-03 | — | — | CN | claimed |
| WO-2022036024-A9 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022066882-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | ONCOLINEA PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | claimed |
| US-20220072087-A1 | SPECIFIC COMBINATION THERAPY FOR TREATMENT OF PANCREATIC CANCER | BIOLINERX LTD. (IL) | 2022-03-10 | — | — | US | claimed |
| CN-114069846-A | Freezing station wireless monitoring system established based on monitoring node with self-contained power supply | 北京中煤矿山工程有限公司 | 2022-02-18 | — | — | CN | claimed |
| WO-2022036024-A2 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-02-17 | — | — | WO | claimed |